Skip to main content

Table 4 2-year and 5-year rates of bRFS and DMFS

From: Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Sub-group

2-year rate (%)

95% CI

5-year rate (%)

95% CI

bRFS

 FHR

91.6

87.7–95.5

69.2

61.9–76.5

 UHR

78.8

70.0–87.6

66.2

54.6–77.8

vHigh Risk

79.4

72.0–86.8

58.2

48.8–67.6

DMFS

 FHR

96.5

94.0–99.0

88.0

83.1–92.9

 UHR

93.0

87.5–98.5

81.2

71.6–90.8

vHigh risk

93.2

88.7–97.7

78.4

70.8–86.0

  1. Abbreviations: bRFS biochemical relapse-free survival, CI confidence interval, DMFS distant metastases-free survival